- Home
- PCM vs ACRV Comparison
PCM vs ACRV Comparison
Compare PCM & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PCM | ACRV |
|---|---|---|
| Founded | 1993 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 66.8M | 74.0M |
| IPO Year | 1994 | 2022 |
Fundamental Metrics
Financial Performance| Metric | PCM | ACRV |
|---|---|---|
| Price | $5.27 | $2.03 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $11.67 |
| AVG Volume (30 Days) | 61.6K | ★ 333.4K |
| Earning Date | 01-01-0001 | 05-08-2026 |
| Dividend Yield | ★ 11.68% | N/A |
| EPS Growth | N/A | ★ 15.13 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $568.17 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.22 | $1.27 |
| 52 Week High | $6.76 | $3.56 |
Technical Indicators
Market Signals| Indicator | PCM | ACRV |
|---|---|---|
| Relative Strength Index (RSI) | 25.78 | 51.68 |
| Support Level | $5.26 | $1.38 |
| Resistance Level | $5.83 | $2.20 |
| Average True Range (ATR) | 0.07 | 0.12 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 15.42 | 2.61 |
Price Performance
Historical ComparisonAbout PCM PCM Fund Inc.
Pcm Fund Inc is a closed-end investment management company. Its investment objective is to seek current income as a primary focus and also capital appreciation. The Fund invests in agency-guaranteed mortgage-backed securities, private-label mortgage-backed securities, high-yield corporate debt securities, and commercial mortgage-backed securities.
About ACRV Acrivon Therapeutics Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1; ACR-2316 a selective, dual WEE1/PKMYT1 inhibitor; and ACR-6840, a development candidate targeting CDK11. It has one reportable segment focused on the research and development of precision oncology therapies.